Eicosapentaenoic Acid And Statin Treatment Associated With Better Clinical Outcomes
Author: Nosaka K, et al
Reference: Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol 2017;228:173-179.
Design: Randomized controlled trial.
Participants: Two hundred forty-one patients with acute coronary syndrome (myocardial infarction or unstable angina).
Study Medication and Dosage: Pivastatin (a statin drug) with or without 1,800 mg per day of eicosapentaenoic acid (EPA), begun within 24 hours after percutaneous coronary intervention.
Primary Outcome Measure: Cardiovascular events occurring within 1 year, including death from a cardiovascular cause, nonfatal stroke, nonfatal myocardial infarction, and revascularization.
Key Findings: The incidence of cardiovascular events (9.2% vs. 20.2%; p = 0.02) and cardiovascular disease-related mortality (0.8% vs. 4.2%; p = 0.04) were significantly lower in the group receiving EPA than in the group non receiving EPA.
Practice Implications: The results of this study indicate that the addition of EPA to a statin drug, as compared with a statin drug alone, decreased the incidence of cardiovascular events after percutaneous coronary intervention in patients with acute coronary syndrome.